# ASCO 2026

Type: conference

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/asco-2026
Canonical HTML page: https://getbiobrief.com/entity/asco-2026

## Recent coverage (1 stories)

### CS2009's 3-in-1 Antibody Shows OS Edge Over PD-1+VEGF Combos at ASCO 2026
2026-06-15 04:21:44 · Sentiment: Positive · Impact: 7/10 · Sources: 2

At ASCO 2026, CStone's CS2009 trispecific antibody targeting PD-1, VEGF, and CTLA-4 revealed a differentiated safety profile and preliminary overall survival potential, positioning it as a next-gen backbone candidate that may outperform current PD-1/VEGF combos and revive CTLA-4 targeting.
Full story: https://getbiobrief.com/story/cs2009-3-in-1-targeting-os-edge-asco-2026

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.